New hope for cancer Survivors' debilitating hot flashes?
NCT ID NCT06917313
Summary
This study is testing if a daily pill called fezolinetant can reduce the frequency and severity of hot flashes in women who are taking hormone therapy for early-stage breast cancer. Researchers will compare the pill's effects against a placebo in 92 participants over 12 weeks. The main goal is to see if the treatment improves quality of life by easing this common and disruptive side effect.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITINGColumbus, Ohio, 43201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale University
RECRUITINGNew Haven, Connecticut, 06511, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.